The CEO of Seoul based Bridge Biotherapeutics discusses the importance of drug development experience - a lead program in IPF is scheduled to have a key phase 2 readout next spring

blonca9
Nov 27, 2024
1 min read

CEO Jame Lee, a founder of multiple biotech companies, describes the operational experience that he suggests is a key differentiator for the company. He then walks us through two lead programs - an autotaxin inhibitor for IPF and a pellino1 inhibitor for inflammatory conditions.

Recent Posts

See All

On its 10-year anniversary, Arcus Biosciences is taking its 4th molecule into pivotal studies. Co-Founder & CEO Terry Rosen talks HIF-2⍺, TIGIT, and CD73

Siren Biotechnology is using an online platform to raise up to $5 million from the public in a "community round" - it might be a new avenue of funding for biotech companies

Theravance Biopharma has a key pivotal trial readout scheduled for late '25 / early '26 in symptomatic neurogenic orthostatic hypotension (nOH) in patients with multiple system atrophy (MSA)

The CEO of Seoul based Bridge Biotherapeutics discusses the importance of drug development experience - a lead program in IPF is scheduled to have a key phase 2 readout next spring

Recent Posts

Join the BiotechTV mailing list

Follow BiotechTV

Sponsors

Sponsor Spotlight